Olfr560 Inhibitors
Olfr560, an olfactory receptor, plays a pivotal role in the detection and transduction of specific odorant signals. Functioning as a G protein-coupled receptor (GPCR), Olfr560 activates intracellular signaling pathways, primarily involving cAMP, MAPK/ERK, PI3K/Akt, and calcium-dependent processes. The receptor's activation triggers a cascade of events leading to the perception of olfactory stimuli. Inhibition of Olfr560 involves targeted modulation of these signaling pathways, either directly through competitive binding or indirectly by influencing broader cellular processes. Quercetin, a flavonoid, competitively binds to Olfr560, disrupting the cAMP signaling pathway and impeding normal receptor functioning. Iodoacetic acid, an irreversible inhibitor, alters the cellular redox balance, indirectly suppressing Olfr560 expression. Inhibitors like SB-203580, U0126, PD98059, and LY294002 target specific kinases in the MAPK/ERK and PI3K/Akt pathways, influencing Olfr560 activity downstream. Wortmannin, a PI3K inhibitor, modulates Olfr560 indirectly by disrupting the PI3K pathway.
Calcium chelator BAPTA-AM and ryanodine receptor inhibitor Dantrolene impact Olfr560 by altering calcium-dependent processes crucial for olfactory signaling. Compounds like 2-Deoxy-D-glucose and cycloheximide, affecting glycolysis and protein synthesis, respectively, indirectly suppress Olfr560 by disrupting cellular energy metabolism and translation processes. Rapamycin, an mTOR inhibitor, influences Olfr560 indirectly by targeting the mTOR pathway. In summary, inhibiting Olfr560 involves precise modulation of its signaling pathways, either directly through competitive binding or indirectly by influencing broader cellular processes, leading to altered expression and function of the olfactory receptor. The intricate network of biochemical events underscores the complexity of olfactory signal transduction and provides potential avenues for targeted modulation in research settings.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Flavonoid inhibiting Olfr560 by disrupting the cAMP signaling pathway. Quercetin competitively binds to olfactory receptors, modulating cellular processes downstream and impeding the normal functioning of Olfr560. | ||||||
Iodoacetic acid | 64-69-7 | sc-215183 sc-215183A | 10 g 25 g | $57.00 $99.00 | ||
Irreversible inhibitor affecting Olfr560 through covalent modification. Iodoacetic acid disrupts cellular redox balance, indirectly suppressing Olfr560 expression and signaling by altering the intracellular environment. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor influencing Olfr560 indirectly. SB-203580 disrupts the MAPK pathway, leading to altered expression and function of Olfr560 as a downstream consequence of its impact on the broader signaling network. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor influencing Olfr560 through the PI3K/Akt pathway. Wortmannin disrupts the PI3K pathway, modulating Olfr560 activity by interfering with downstream effectors crucial for its normal functioning. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Calcium chelator indirectly inhibiting Olfr560. BAPTA-AM disrupts calcium-dependent processes, impacting olfactory signaling pathways and consequently leading to decreased expression and function of Olfr560. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor affecting Olfr560 through the MAPK/ERK pathway. U0126 disrupts the MAPK/ERK signaling cascade, resulting in altered expression and function of Olfr560 as a downstream consequence of pathway inhibition. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
Glycolysis inhibitor indirectly influencing Olfr560. 2-Deoxy-D-glucose disrupts cellular energy metabolism, modulating olfactory signaling pathways and leading to suppressed expression and activity of Olfr560. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Protein synthesis inhibitor affecting Olfr560 indirectly. Cycloheximide disrupts translation processes, leading to altered expression and turnover of Olfr560 as a downstream consequence of impaired protein synthesis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
ERK inhibitor influencing Olfr560 through the MAPK/ERK pathway. PD98059 disrupts the MAPK/ERK signaling cascade, resulting in altered expression and function of Olfr560 as a downstream consequence of pathway inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor affecting Olfr560 through the PI3K/Akt pathway. LY294002 disrupts the PI3K pathway, modulating Olfr560 activity by interfering with downstream effectors crucial for its normal functioning. | ||||||